High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Download PDF Copy

Sep 13 2010

NewsGuard 100/100 Score

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo. The study was presented at the Plenary General Session of International Liver Cancer Association Fourth Annual Conference (ILCA2010) on September 11, 2010 (Presentation number O-014). Kowa plans to submit peretinoin to regulatory authorities in Japan for marketing authorization.

Source:

Kowa Company, Ltd.

Posted in: Drug Trial News | Medical Condition News | Disease/Infection News

Tags: Cancer, Carcinoma, Cirrhosis, Headache, Hepatitis, Hepatitis A, Hepatitis B, Hepatitis B Virus, Hepatitis C, Hepatitis D, Hepatitis E, Hepatocellular Carcinoma, Hospital, Hypercholesterolemia, Livalo, Liver, Liver Cancer, Pitavastatin, Placebo, Radiofrequency Ablation, Virology, Virus, Vitamin A

Comments (0)

Download PDF Copy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.